Clinical trial Recruiting at 1 site Observational Ages 18 and up

Predicting HFNO failure within 72 hours using a physiology-informed model at 30 minutes

Official title: A Physiology-Informed Dual-Domain Model for 30-Minute Reassessment to Predict Endotracheal Intubation Within 72 Hours After High-Flow Nasal Oxygen Initiation in Adults With Acute Hypoxemic Respiratory Failure: A Retrospective Derivation and Multicenter Prospective Validation Study

Run by Ruijin Hospital · NCT07366541 · Data updated 2026-11-12

This study tests a model that uses Heart–lung physiology and 30-minute data to see if high-flow nasal oxygen will fail in adults with acute hypoxemic respiratory failure.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment115 (estimated)
SponsorRuijin Hospital
Academic / other
Locations1 site (Shanghai, Shanghai Municipality)
StatusRecruiting
StartedMay 1, 2025
Main results expectedDecember 31, 2026
Study endsDecember 31, 2026
Registry record updatedOctober 8, 2026
Trial IDNCT07366541 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (≥18 years) with acute hypoxemic respiratory failure requiring HFNO and at least one high-risk criterion (PaO2/FiO2 ≤200 or FiO2 ≥0.40, RR ≥25, APACHE II ≥12, or bilateral infiltrates).

Probably not a fit

Patients without early physiologic deterioration or those whose respiratory failure is due to non-hypoxemic processes may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an ambispective, single-center observational study conducted at Ruijin Hospital in Shanghai. It first derived a dual-domain logistic model from baseline EFI, baseline PaCO2, and 0–30 minute changes in respiratory rate and SpO2 using retrospective data, then validated the model retrospectively with a later cohort, and is now prospectively validating it in an independent cohort. The primary outcome is endotracheal intubation within 72 hours of initiating high-flow nasal oxygen. Eligible adults have acute hypoxemic respiratory failure requiring HFNO, with several high-risk criteria, and must be able to undergo electrical impedance tomography monitoring. Exclusions include immediate intubation needs, neuromuscular limitation, pregnancy, contraindications to EIT, DNR orders, or hypercapnic respiratory failure as the primary diagnosis.

Why it matters

Potential benefit: If successful, the model could help clinicians identify HFNO patients at risk of failure earlier, potentially guiding timely escalation of care.

How similar studies have gone: Previous work in this area has shown promise with imaging- and physiology-informed approaches, but prospective multicenter validation remains limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria (must meet all):

* Age ≥18 years
* Acute hypoxemic respiratory failure (AHRF) requiring HFNO initiation
* At least one of the following high-risk criteria: a) PaO₂/FiO₂ ≤200 mmHg or FiO₂ ≥0.40 to maintain SpO₂ ≥92%; b) Respiratory rate ≥25/min; c) APACHE II score ≥12; d) Bilateral infiltrates on chest imaging

Exclusion Criteria:

* Neuromuscular disease affecting spontaneous breathing
* Pregnancy
* Contraindication to EIT (e.g., chest wall wounds, pacemaker)
* Do-not-intubate order
* Hypercapnic respiratory failure as primary diagnosis (PaCO₂ \>50 mmHg with pH \<7.30 at baseline, unless mixed mechanism)

Where it's running

  • Department of Critical Care Medicine,Ruijin Hospital,Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai Municipality, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.